This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MARY J. HENN, M.D.; THOMAS W. PARKIN, M.D.; MALCOLM M. HARGRAVES, M.D.; HOWARD M. ODEL, M.D.

AMA Arch Intern Med. 1955;95(6):857-862.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

BETWEEN April, 1953, and August, 1954, nine reports * appeared in the literature describing a variety of delayed toxic reactions which may develop in hypertensive patients who are taking hydralazine hydrochloride. It is of interest that positive L. E.-cell phenomena have been noted in six patients (Table 1) receiving this chemical.

We wish to report data concerning a patient in whom the clinical picture of acute systemic lupus erythematosus and a positive L. E.-cell phenomenon developed. This patient recovered when administration of hydralazine hydrochloride was discontinued.

A married white woman, 58 years old, has been examined periodically at the Mayo Clinic since 1942 and found to be relatively well. From 1945 until August, 1950, her blood pressure gradually increased from 160/90 to 210/100. In August, 1950, oral administration of potassium thiocyanate was begun, with satisfactory results until January, 1951, at which time a skin eruption developed, which necessitated the discontinuance . . . [Full Text PDF of this Article]

Author Affiliations
Rochester, Minn.

Footnotes
The Mayo Foundation is a part of the Graduate School of the University of Minnesota.

Fellow in Medicine, Mayo Foundation (Dr. Henn); Section of Medicine Mayo Clinic and Mayo Foundation (Drs. Parkin, Hargraves, and Odel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?